GE Healthcare today announced pooled results from phase III brain autopsy and
biopsy studies on the investigational PET amyloid imaging agent,
[^18F]flutemetamol, which showed a strong concordance between
[^18F]flutemetamol images and Alzheimer's disease-associated beta amyloid
brain pathology.^1 [^18F]Flutemetamol is a PET imaging agent being developed
by GE Healthcare for the detection of beta amyloid deposits in the brain. The
data from the phase III studies further confirm the potential application of
[^18F]flutemetamol as an imaging agent to detect beta amyloid plaques.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in